A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

Summary

Compare the effect of exenatide (therapeutic and supratherapeutic concentrations), moxifloxacin and placebo on the QT interval.

Timeline

Start

2011-02

Primary completion

2011-04

Completion

2011-05

Outcome

Met primary endpoint

registry Least Squares Mean Difference -1.36 (90% CI -2.21 to -0.50) NCT01297062 ↗

registry Least Squares Mean Difference -2.02 (90% CI -2.88 to -1.16) NCT01297062 ↗

registry Least Squares Mean Difference -1.13 (90% CI -2.11 to -0.15) NCT01297062 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Exenatide	Peptide	—	Intravenous
Comparator	Moxifloxacin	Small molecule	400 mg	Oral

Indications

No indication recorded.